Related Experiment Video

Updated: Jun 14, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Writers, readers, and erasers RNA modifications and drug resistance in cancer

Di Chen1, Xinyu Gu2, Yeltai Nurzat3

  • 1Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 1 Jianshe East Road, Erqi District, Zhengzhou, 450052, Henan, China.

Molecular Cancer
|August 30, 2024
PubMed

Insights

RNA modifications like N6-methyladenosine (m6A) drive cancer drug resistance by altering gene expression. Targeting these RNA regulators offers a new strategy to improve cancer treatment efficacy.

Area of Science:

  • Molecular Biology
  • Epigenetics
  • Oncology

Background:

  • Drug resistance in cancer reduces treatment effectiveness, causing recurrence and metastasis.
  • Epigenetic alterations, specifically RNA modifications, are key drivers of this resistance.
  • Prevalent RNA modifications include N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), pseudouridine (Ψ), and adenosine-to-inosine (A-to-I) editing.

Purpose of the Study:

  • To review the role of major RNA modifications in cancer drug resistance.
  • To examine the regulatory mechanisms of RNA modifications in cancer progression and drug resistance.
  • To identify current limitations and future directions in targeting RNA modifications for cancer therapy.

Main Methods:

  • Literature review of recent research on RNA modifications and cancer drug resistance.
  • Analysis of the impact of specific RNA modifications (m6A, m1A, m5C, m7G, Ψ, A-to-I) on cancer.
  • Examination of the regulatory networks ('writers,' 'readers,' 'erasers') involved in RNA modification.

Main Results:

  • RNA modifications significantly influence RNA processing (splicing, translation, stability, degradation).
  • Aberrant RNA modifications are linked to cancer hallmarks like proliferation, stemness, invasion, and apoptosis, contributing to drug resistance.
  • Targeting RNA modification regulators presents a potential therapeutic strategy to overcome drug resistance.

Conclusions:

  • RNA modifications are critical regulators of gene expression and play a significant role in the development of cancer drug resistance.
  • Understanding the mechanisms by which RNA modifications confer resistance is crucial for developing novel therapeutic interventions.
  • Further research is needed to fully elucidate these mechanisms and translate findings into effective clinical strategies.
Keywords:
Abnormal expressionCombination therapyDrug resistanceEpigenetic alterationsRNA modification regulators

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.7K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K